Text Size

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

This study has been terminated.
Sponsor:
Information provided by:
Mitsubishi Tanabe Pharma Corporation
ClinicalTrials.gov Identifier:
NCT00059644
First received: April 29, 2003
Last updated: June 23, 2005
Last verified: June 2005
History of Changes
  Purpose

Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.


Condition Intervention Phase
Peripheral Vascular Disease
 Drug: Ecraprost in lipid emulsion
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM for the Treatment of Critical Leg Ischemia

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Mitsubishi Tanabe Pharma Corporation:

Primary Outcome Measures:
  • Reduction in proportion of subjects who experience a major amputation.
  • Reduction in proportion of subjects who die within 6 months from treatment initiation.

Secondary Outcome Measures:
  • Reduction in major amputation rate only.
  • Reduction in critical cardiovascular events.
  • Improvement in complete ulcer healing.
  • Improvement in pain at rest.
  • Improvement in quality of life.
  • Improvement in hemodynamic measurements.
  • Improvement in neuropathy.

Estimated Enrollment: 560
Study Start Date: July 2001
Estimated Study Completion Date: June 2004
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Critical leg ischemia (CLI) defined as distal extremity pain at rest, or peripheral ischemic ulcer(s), with severe hemodynamic impairment as diagnosed by ankle systolic pressure, toe systolic pressure or TcPO2
  • The subject has exhausted all standard revascularization treatment options at this time.

Exclusion Criteria:

  • Subjects with a previous major amputation (at or above ankle)
  • Subjects with end stage renal disease (ESRD) defined as significant renal dysfunction evidenced by estimated creatinine clearance of < 20 cc/min, or receiving chronic hemodialysis therapy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00059644

  Show 27 Study Locations
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00059644     History of Changes
Other Study ID Numbers: WFI 01-01
Study First Received: April 29, 2003
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by Mitsubishi Tanabe Pharma Corporation:
Ecraprost in lipid emulsion
CLI
peripheral
 vascular
amputation
Critical Limb Ischemia due to peripheral arterial disease

Additional relevant MeSH terms:
Ischemia
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Pathologic Processes
 Cardiovascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases

ClinicalTrials.gov processed this record on May 16, 2013